Insights

New Market Expansion APEIRON Biologics AG recently launched a Phase Ib trial for APN401 targeting solid tumors, indicating a potential opportunity for market expansion in the oncology sector.

Strategic Partnerships The collaboration with Domainex to develop inhibitors for E3 ubiquitin ligase Cbl-b showcases APEIRON's focus on strategic partnerships, presenting avenues for joint sales efforts and new client acquisition.

Financial Growth Receiving $19.9M in financing for the development of drug candidates against COVID-19 and immuno-oncology projects demonstrates APEIRON's financial stability and potential for investments, highlighting opportunities for sales growth.

Acquisition Potential The recent acquisition of APEIRON Biologics AG by Ligand Pharmaceuticals Incorporated for $100M indicates a potential window for exploring partnerships or sales agreements with the acquiring entity.

Product Diversification With one product on the market and several others in clinical to pre-clinical stages, APEIRON Biologics AG presents opportunities for diversified product sales strategies and cross-selling within their portfolio.

APEIRON Biologics AG Tech Stack

APEIRON Biologics AG uses 8 technology products and services including W3 Total Cache, jQuery Migrate, Lightbox, and more. Explore APEIRON Biologics AG's tech stack below.

W3 Total Cache

Caching

jQuery Migrate

Javascript Libraries

Lightbox

Javascript Libraries

RSS

Miscellaneous

Debian

Operating Systems

Bootstrap

UI Frameworks

Animate.css

UI Frameworks

Apache HTTP Server

Web Servers

APEIRON Biologics AG Email Formats	Example	Percentage
first.last@apeiron-biologics.com	John.Doe@apeiron-biologics.com	50%
first.last@apeiron-biologics.com	John.Doe@apeiron-biologics.com	50%

APEIRON Biologics AG Email Formats

Example

Percentage

first.last@apeiron-biologics.com

John.Doe@apeiron-biologics.com

50%

first.last@apeiron-biologics.com

John.Doe@apeiron-biologics.com

50%

Frequently Asked Questions

Where is APEIRON Biologics AG's headquarters located?

APEIRON Biologics AG's main headquarters is located at Campus-Vienna-Biocenter 5 Wien, Wien 1030 AT. The company has employees across 2 continents, including EuropeNorth America.

What is APEIRON Biologics AG's official website and social media links?

APEIRON Biologics AG's official website is apeiron-biologics.com and has social profiles on LinkedIn.

What is APEIRON Biologics AG's SIC code NAICS code?

APEIRON Biologics AG's SIC code is 8731 - Commercial Physical and Biological Research NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does APEIRON Biologics AG have currently?

As of April 2024, APEIRON Biologics AG has approximately 12 employees across 2 continents, including EuropeNorth America. Key team members include Chief Executive Officer: H. L.Chief Financial Officer: D. C.Head Of Clinical Operations: S. B.. Explore APEIRON Biologics AG's employee directory with LeadIQ.

What industry does APEIRON Biologics AG belong to?

APEIRON Biologics AG operates in the Biotechnology Research industry.

What technology does APEIRON Biologics AG use?

APEIRON Biologics AG's tech stack includes W3 Total CachejQuery MigrateLightboxRSSDebianBootstrapAnimate.cssApache HTTP Server.

What is APEIRON Biologics AG's email format?

APEIRON Biologics AG's email format typically follows the pattern of . Find more APEIRON Biologics AG email formats with LeadIQ.

When was APEIRON Biologics AG founded?

APEIRON Biologics AG was founded in 2003.

APEIRON Biologics AG

Biotechnology ResearchWien, Austria11-50 Employees

APEIRON Biologics is a privately held European biotech company based in Vienna, Austria, focused on the discovery and development of treatments for respiratory diseases and novel cancer immunotherapies.  

Our company has a well balanced portfolio with one product on the market and several promising products from clinical to pre-clinical stages. As for the product on the market, APEIRON received EU marketing approval for APN311 (Dinutuximab beta, Qarziba®) in May 2017 for the treatment of pediatric neuroblastoma patients. We out-licensed Qarziba® globally to EUSA Pharma Ltd, for which it holds exclusive rights to this product.

APEIRON’s key projects and technologies are bolstered by a strong patent portfolio with broad territorial coverage. Our development expertise is validated through partnerships with leading global pharmaceutical companies and academic institutions.

Insights

Similar companies to APEIRON Biologics AG

OSE Immunotherapeutics

Nektar Therapeutics

Orphazyme A/S

Innovimmune Biotherapeutics

Innate Pharma